Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;23(1):30-32.
doi: 10.1016/S1473-3099(22)00816-7. Epub 2022 Dec 7.

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB

Ryuta Uraki  1 , Mutsumi Ito  2 , Yuri Furusawa  1 , Seiya Yamayoshi  1 , Kiyoko Iwatsuki-Horimoto  2 , Eisuke Adachi  3 , Makoto Saito  4 , Michiko Koga  4 , Takeya Tsutsumi  4 , Shinya Yamamoto  5 , Amato Otani  3 , Maki Kiso  2 , Yuko Sakai-Tagawa  2 , Hiroshi Ueki  1 , Hiroshi Yotsuyanagi  4 , Masaki Imai  1 , Yoshihiro Kawaoka  6
Affiliations

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB

Ryuta Uraki et al. Lancet Infect Dis. 2023 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

YK is supported by grants from the Center for Research on Influenza Pathogenesis (HHSN272201400008C) and from the Center for Research on Influenza Pathogenesis and Transmission (75N93021C00014), funded by the National Institute of Allergy and Infectious Disease; and by a Research Program on Emerging and Reemerging Infectious Diseases (JP21fk0108552 and JP21fk0108615), a Project Promoting Support for Drug Discovery (JP21nf0101632), the Japan Program for Infectious Diseases Research and Infrastructure (JP22wm0125002), and a grant (JP223fa627001) from the Japan Agency for Medical Research and Development. All other authors declare no competing interests. RU, MI, and YF contributed equally.

Figures

Figure
Figure
Antibody responses to SARS-CoV-2 omicron variants (A) Neutralising antibody titres of human plasma obtained from individuals immunised with a third dose of BNT162b2 or mRNA-1273 vaccine. Samples were collected 180–189 days after the third immunisation (n=20). (B) Neutralising antibody titres of human plasma obtained from individuals immunised with four doses of BNT162b2 or mRNA-1273 vaccine. Samples were collected 33–57 days after the fourth immunisation (n=20). (C) Neutralising antibody titres of human plasma obtained from individuals who were infected with omicron BA.2 after three doses of BNT162b2 or mRNA-1273 vaccine. Samples were collected 29–89 days after symptom onset (n=10). Each dot represents data from one individual. The lower limit of detection (value=10) is indicated by the horizontal dashed line. Samples under the detection limit (<10-fold dilution) were assigned an FRNT50 value of 10 and are represented by X. Geometric mean titres are shown. FRNT50=50% focus reduction neutralisation titre.
See this image and copyright information in PMC

References

    1. Miller NL, Clark T, Raman R, Sasisekharan R. Insights on the mutational landscape of the SARS-CoV-2 omicron variant receptor-binding domain. Cell Rep Med. 2022;3:100527. - PMC - PubMed
    1. Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against omicron BQ.1.1 and XBB subvariants. N Engl J Med (in press). - PMC - PubMed
    1. Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent omicron RBD evolution. bioRxiv. 2022 doi: 10.1101/2022.09.15.507787. published online Sept 16. - DOI - PMC - PubMed

Publication types